Medindia
Medindia LOGIN REGISTER
Advertisement

Additional Data From Multiple Phase 1 and 2 Studies of S*BIO's Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)

Wednesday, June 1, 2011 General News
Advertisement
--SB1518 Alleviates MF-Associated Splenomegaly and Shows No Myelosuppression and No Exacerbation of Cytopenias-

S*BIO Pte Ltd:

Russo Partners

Hew Yin Chin, Ph.D.

Tony Russo +1 212-845-4251

Associate Director, Corporate Development

[email protected]

Tel: +65 6827 5000 (Singapore)

Andreas Marathovouniotis +1 212-845-4235

[email protected]

[email protected]

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close